Drilldown: Medicines

None (3) · Codeine (2)

Other values:

Search

None (47) · (multiple, generic dominant) (1) · Benzedrex (1) · Caplyta (1) · Darvon (1) · Demerol (1) · Dilaudid (1) · Dolophine (1) · Duragesic (1) · Nubain (1) · Nucynta (1) · Opana (1) · Rexulti (1) · Stadol (1) · Suboxone (1) · Talwin (1) · Vicodin (1) · Vraylar (1)

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-Hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antipsychotic · Antiparkinsonian · Empathogen · Neuroleptic · Cathinone

Other values:

Search

Monoamine releasing agent (8) · Dopamine/norepinephrine reuptake inhibitor (5) · Mu-opioid receptor agonist (4) · Potent mu-opioid receptor agonist (3) · None (2) · Cathinone analogue; monoamine reuptake inhibitor (2) · Dopamine and norepinephrine reuptake inhibitor (2) · Norepinephrine–dopamine reuptake inhibitor (2)

Other values:

Search

None (60) · Mild to moderate pain; cough suppression (low-dose). (1) · Schizophrenia (FDA-approved 2015). Acute manic or mixed episodes of bipolar I disorder. Bipolar I depression (FDA-approved 2019). Adjunctive treatment of major depressive disorder (FDA-approved Dec 2022). (1) · Schizophrenia (FDA-approved 2015). Adjunctive treatment of major depressive disorder (2015). '''Agitation associated with dementia due to Alzheimer disease''' (FDA-approved May 2023, first agent specifically approved for this problem). Investigational for PTSD (combined with sertraline). (1) · Schizophrenia (FDA-approved Dec 2019). Bipolar depression as monotherapy or adjunct to lithium/valproate (FDA-approved Dec 2021). (1)

None (60) · 42 mg PO once daily with food (no titration) (1) · Adult: 15–60 mg every 4 hours as needed. (1) · Schizophrenia: 1 mg PO daily × 4 days, then 2 mg daily × 3 days, then 4 mg daily. MDD adjunct: 0.5-1 mg daily, increase to 2 mg max. AD agitation: 0.5 mg daily, titrate to 2-3 mg daily. (1) · Schizophrenia: 1.5 mg PO daily, increase to 1.5-6 mg as tolerated. Bipolar mania: 1.5 mg, may increase to 3-6 mg. Bipolar depression: 1.5 mg daily for 14 days, then 3 mg. MDD adjunct: 1.5 mg, may increase to 3 mg. (1)

None (60) · 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg tablets (1) · 1.5 mg, 3 mg, 4.5 mg, 6 mg capsules (1) · 42 mg capsules (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (60) · 360 mg/day (1) · 4 mg/d (schizophrenia); 3 mg/d (AD agitation); 3 mg/d (MDD adjunct) (1) · 42 mg/d (1) · 6 mg/d (psychosis/mania); 3 mg/d (depression adjunct) (1)

None (60) · Oral (3) · PO (only formulation marketed in the US). (1)

None (60) · 30–60 min (PO) (1) · Antipsychotic effect over weeks (1) · Weeks for psychosis/depression; AD agitation benefit emerges over weeks (1) · Weeks for psychosis/mood efficacy (1)

None (60) · 4–6 hours (1) · Daily dosing (2) · Daily dosing; active metabolites with very long half-lives (up to 1-3 weeks) (1)

None (60) · 2.5–3 hours (1) · Cariprazine ~2-4 d; major active metabolites desmethyl-cariprazine (DCAR) ~1-3 weeks → 'oral depot' effect with delayed steady-state and reduced effect of missed doses (1) · ~18 hours (terminal) (1) · ~91 hours (1)

None (60) · Adequate oral bioavailability (1) · Limited but adequate; take with food (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1) · ~95% (1)

None (60) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Limited data (1) · Limited data; National Pregnancy Registry available (1) · Limited data; National Pregnancy Registry for Atypical Antipsychotics (1)

None (60) · Rx (3) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1)